Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
 
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2017, Vol. 8 Issue (1) : 7-16     DOI: 10.14336/AD.2016.0627
Review Article |
Potential Biochemical Mechanisms of Lung Injury in Diabetes
Zheng Hong1,2, Wu Jinzi1, Jin Zhen1, Yan Liang-Jun1,*
1Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
2Department of Basic Theory of Traditional Chinese Medicine, College of Basic Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, 250355, China
Download: PDF(1083 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    
Abstract  

Accumulating evidence has shown that the lung is one of the target organs for microangiopathy in patients with either type 1 or type 2 diabetes mellitus (DM). Diabetes is associated with physiological and structural abnormalities in the diabetic lung concurrent with attenuated lung function. Despite intensive investigations in recent years, the pathogenic mechanisms of diabetic lung injury remain largely elusive. In this review, we summarize currently postulated mechanisms of diabetic lung injury. We mainly focus on the pathogenesis of diabetic lung injury that implicates key pathways, including oxidative stress, non-enzymatic protein glycosylation, polyol pathway, NF-κB pathway, and protein kinase c pathway. We also highlight that while numerous studies have mainly focused on tissue or cell damage in the lung, studies focusing on mitochondrial dysfunction in the diabetic lung have remained sketchy. Hence, further understanding of mitochondrial mechanisms of diabetic lung injury should provide invaluable insights into future therapeutic approaches for diabetic lung injury.

Keywords diabetic hyperglycemia      diabetic lung injury      diabetes mellitus      mitochondria      oxidative stress     
Corresponding Authors: Yan Liang-Jun   
About author:

These authors contributed equally to this work

Issue Date: 01 February 2017
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Zheng Hong
Wu Jinzi
Jin Zhen
Yan Liang-Jun
Cite this article:   
Zheng Hong,Wu Jinzi,Jin Zhen, et al. Potential Biochemical Mechanisms of Lung Injury in Diabetes[J]. Aging and disease, 2017, 8(1): 7-16.
URL:  
http://www.aginganddisease.org/EN/10.14336/AD.2016.0627     OR     http://www.aginganddisease.org/EN/Y2017/V8/I1/7
Figure 1.  Hyperglycemia-upregulated pathways that are potentially involved in diabetic lung injury. These include protein glycation, PKC pathway, NF-KB pathway, polyol pathway, and oxidative stress. It should be noted that these pathways may be inter-related. For example, the polyol pathway can also contribute to oxidative stress.
Figure 2.  Possible role of mitochondrial dysfunction in diabetic lung injury. Show is the mitochondrial elements that are involved in cell death. Initial production of mitochondrial ROS can lead to changes in membrane potential and opening of mitochondrial permeability transition pore (MPTP) opening. MPTP opening could further enhance mitochondrial ROS production, forming a vicious cycle that eventually leads to cell death and lung dysfunction.
[1] Pitocco D, Fuso L, Conte EG, Zaccardi F, Condoluci C, Scavone G, et al. (2012). The diabetic lung--a new target organ? Rev Diabet Stud, 9(1): 23-35.
[2] Kuitert LM (2008). The lung in diabetes--yet another target organ? Chron Respir Dis, 5(2): 67-68.
[3] Sandler M (1990). Is the lung a ’target organ’ in diabetes mellitus? Arch Intern Med, 150(7): 1385-1388.
[4] Hsiao YT, Cheng WC, Liao WC, Lin CL, Shen TC, Chen WC, et al. (2015). Type 1 Diabetes and Increased Risk of Subsequent Asthma: A Nationwide Population-Based Cohort Study. Medicine (Baltimore), 94(36): e1466.
[5] Black MH, Anderson A, Bell RA, Dabelea D, Pihoker C, Saydah S, et al. (2011). Prevalence of asthma and its association with glycemic control among youth with diabetes. Pediatrics, 128(4): e839-847.
[6] Carlsson AC, Wandell P, Osby U, Zarrinkoub R, Wettermark B, Ljunggren G (2013). High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden - a challenge for public health. BMC Public Health, 13: 670.
[7] d’Annunzio G, Tosca MA, Pistorio A, Silvestri M, Romanisio G, Lorini R, et al. (2015). Type 1 diabetes mellitus and asthma: A follow-up study. Allergol Immunopathol (Madr), 43(2): 225-227.
[8] Kent BD, Grote L, Ryan S, Pepin JL, Bonsignore MR, Tkacova R, et al. (2014). Diabetes mellitus prevalence and control in sleep-disordered breathing: the European Sleep Apnea Cohort (ESADA) study. Chest, 146(4): 982-990.
[9] Wu Z, Guo J, Huang Y, Cai E, Zhang X, Pan Q, et al. (2016). Diabetes mellitus in patients with pulmonary tuberculosis in an aging population in Shanghai, China: Prevalence, clinical characteristics and outcomes. J Diabetes Complications, 30(2): 237-241.
[10] Ehrlich SF, Quesenberry CPJr., Van Den Eeden SK, Shan J, Ferrara A (2010). Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care, 33(1): 55-60.
[11] Hu Y, Ma Z, Guo Z, Zhao F, Wang Y, Cai L, et al. (2014). Type 1 diabetes mellitus is an independent risk factor for pulmonary fibrosis. Cell Biochem Biophys, 70(2): 1385-1391.
[12] Goto Y, Sato SI, Masuda M (1974). Causes of death in 3151 diabetic autopsy cases. Tohoku J Exp Med, 112(4): 339-353.
[13] Klekotka RB, Mizgala E, Krol W (2015). The etiology of lower respiratory tract infections in people with diabetes. Pneumonol Alergol Pol, 83(5): 401-408.
[14] Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, et al. (2005). Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis, 41(3): 281-288.
[15] Silwer H, Oscarsson PN (1958). Incidence and coincidence of diabetes mellitus and pulmonary tuberculosis in a Swedish county. Acta Med Scand Suppl, 335: 1-48.
[16] Thanh NP, Khue PM, Sy DN, Strobel M (2015). [Diabetes among new cases of pulmonary tuberculosis in Hanoi, Vietnam]. Bull Soc Pathol Exot.
[17] Balakrishnan S, Vijayan S, Nair S, Subramoniapillai J, Mrithyunjayan S, Wilson N, et al. (2012). High diabetes prevalence among tuberculosis cases in Kerala, India. PLoS One, 7(10): e46502.
[18] Kim SJ, Hong YP, Lew WJ, Yang SC, Lee EG (1995). Incidence of pulmonary tuberculosis among diabetics. Tuber Lung Dis, 76(6): 529-533.
[19] McCloud LL, Parkerson JB, Zou L, Rao RN, Catravas JD (2004). Reduced pulmonary endothelium-bound angiotensin converting enzyme activity in diabetic rabbits. Vascul Pharmacol, 41(4-5): 159-165.
[20] Williams JG, Morris AI, Hayter RC, Ogilvie CM (1984). Respiratory responses of diabetics to hypoxia, hypercapnia, and exercise. Thorax, 39(7): 529-534.
[21] Kida K, Utsuyama M, Takizawa T, Thurlbeck WM (1983). Changes in lung morphologic features and elasticity caused by streptozotocin-induced diabetes mellitus in growing rats. Am Rev Respir Dis, 128(1): 125-131.
[22] Eren G, Cukurova Z, Hergunsel O, Demir G, Kucur M, Uslu E, et al. (2010). Protective effect of the nuclear factor kappa B inhibitor pyrrolidine dithiocarbamate in lung injury in rats with streptozotocin-induced diabetes. Respiration, 79(5): 402-410.
[23] Hu JF, Zhang GJ, Wang L, Kang PF, Li J, Wang HJ, et al. (2014). Ethanol at low concentration attenuates diabetes induced lung injury in rats model. J Diabetes Res, 2014: 107152.
[24] Alkan M, Celik A, Bilge M, Kiraz HA, Kip G, Ozer A, et al. (2015). The effect of levosimendan on lung damage after myocardial ischemia reperfusion in rats in which experimental diabetes was induced. J Surg Res, 193(2): 920-925.
[25] Yang J, Tan Y, Zhao F, Ma Z, Wang Y, Zheng S, et al. (2011). Angiotensin II plays a critical role in diabetic pulmonary fibrosis most likely via activation of NADPH oxidase-mediated nitrosative damage. Am J Physiol Endocrinol Metab, 301(1): E132-144.
[26] Liang JQ, Ding CH, Ling YL, Xu HB, Lu P, Xian XH (2007). [The protective function of puerarin to the injury of the lung and its mechanisms during diabetes]. Zhongguo Ying Yong Sheng Li Xue Za Zhi, 23(3): 355-358.
[27] Luo X, Wu J, Jing S, Yan LJ (2016). Hyperglycemic Stress and Carbon Stress in Diabetic Glucotoxicity. Aging Dis, 7(1): 90-110.
[28] Wu J, Jin Z, Zheng H, Yan LJ (2016). Sources and implications of NADH/NAD+ redox imbalance in diabetes and its complications. Diabetes Metab Syndr Obes, 9: 145-153.
[29] Teeter JG, Riese RJ (2008). Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study: response to Yeh et al. Diabetes Care, 31(10): e82.
[30] Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Cox CE, et al. (2008). Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care, 31(4): 741-746.
[31] Dennis RJ, Maldonado D, Rojas MX, Aschner P, Rondon M, Charry L, et al. (2010). Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study. BMC Pulm Med, 10: 38.
[32] Lange P, Groth S, Kastrup J, Mortensen J, Appleyard M, Nyboe J, et al. (1989). Diabetes mellitus, plasma glucose and lung function in a cross-sectional population study. Eur Respir J, 2(1): 14-19.
[33] Engstrom G, Hedblad B, Nilsson P, Wollmer P, Berglund G, Janzon L (2003). Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort study. J Intern Med, 253(5): 574-581.
[34] Suresh V, Reddy A, Mohan A, Rajgopal G, Satish P, Harinarayan C, et al. (2011). High prevalence of spirometric abnormalities in patients with type 1 diabetes mellitus. Pediatr Endocrinol Diabetes Metab, 17(2): 71-75.
[35] van Gent R, Brackel HJ, de Vroede M, van der Ent CK (2002). Lung function abnormalities in children with type I diabetes. Respir Med, 96(12): 976-978.
[36] Davis WA, Knuiman M, Kendall P, Grange V, Davis TM, Fremantle Diabetes S (2004). Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care, 27(3): 752-757.
[37] Yeh F, Dixon AE, Marion S, Schaefer C, Zhang Y, Best LG, et al. (2011). Obesity in adults is associated with reduced lung function in metabolic syndrome and diabetes: the Strong Heart Study. Diabetes Care, 34(10): 2306-2313.
[38] Fontaine-Delaruelle C, Viart-Ferber C, Luyton C, Couraud S (2016). [Lung function in patients with diabetes mellitus]. Rev Pneumol Clin, 72(1): 10-16.
[39] Aparna (2013). Pulmonary function tests in type 2 diabetics and non-diabetic people -a comparative study. J Clin Diagn Res, 7(8): 1606-1608.
[40] Dharwadkar AR, Dharwadkar AA, Banu G, Bagali S (2011). Reduction in lung functions in type-2 diabetes in Indian population: correlation with glycemic status. Indian J Physiol Pharmacol, 55(2): 170-175.
[41] Huang H, Guo Q, Li L, Lin S, Lin Y, Gong X, et al. (2014). Effect of type 2 diabetes mellitus on pulmonary function. Exp Clin Endocrinol Diabetes, 122(6): 322-326.
[42] Kim CH, Kim HK, Kim EH, Bae SJ, Jung YJ, Choi J, et al. (2015). Association of restrictive ventilatory dysfunction with the development of prediabetes and type 2 diabetes in Koreans. Acta Diabetol, 52(2): 357-363.
[43] Saidullah B, Muralidhar K, Fahim M (2014). Onset of diabetes modulates the airway smooth muscle reactivity of guinea pigs: role of epithelial mediators. J Smooth Muscle Res, 50: 29-38.
[44] Fuso L, Pitocco D, Longobardi A, Zaccardi F, Contu C, Pozzuto C, et al. (2012). Reduced respiratory muscle strength and endurance in type 2 diabetes mellitus. Diabetes Metab Res Rev, 28(4): 370-375.
[45] Nakajima K, Kubouchi Y, Muneyuki T, Ebata M, Eguchi S, Munakata H (2008). A possible association between suspected restrictive pattern as assessed by ordinary pulmonary function test and the metabolic syndrome. Chest, 134(4): 712-718.
[46] Litonjua AA, Lazarus R, Sparrow D, Demolles D, Weiss ST (2005). Lung function in type 2 diabetes: the Normative Aging Study. Respir Med, 99(12): 1583-1590.
[47] Sternberg M, Cohen-Forterre L, Peyroux J (1985). Connective tissue in diabetes mellitus: biochemical alterations of the intercellular matrix with special reference to proteoglycans, collagens and basement membranes. Diabete Metab, 11(1): 27-50.
[48] Hamlin CR, Kohn RR, Luschin JH (1975). Apparent accelerated aging of human collagen in diabetes mellitus. Diabetes, 24(10): 902-904.
[49] Antonelli Incalzi R, Fuso L, Giordano A, Pitocco D, Maiolo C, Calcagni ML, et al. (2002). Neuroadrenergic denervation of the lung in type I diabetes mellitus complicated by autonomic neuropathy. Chest, 121(2): 443-451.
[50] Antonelli Incalzi R, Fuso L, Pitocco D, Basso S, Trove A, Longobardi A, et al. (2007). Decline of neuroadrenergic bronchial innervation and respiratory function in type 1 diabetes mellitus: a longitudinal study. Diabetes Metab Res Rev, 23(4): 311-316.
[51] Jenkinson KM, Reid JJ (2000). Altered non-adrenergic non-cholinergic neurotransmission in gastric fundus from streptozotocin-diabetic rats. Eur J Pharmacol, 401(2): 251-258.
[52] Lee MJ, Coast JR, Hempleman SC, Baldi JC (2016). Type 1 Diabetes Duration Decreases Pulmonary Diffusing Capacity during Exercise. Respiration, 91(2): 164-170.
[53] Martin-Frias M, Lamas A, Lara E, Alonso M, Ros P, Barrio R (2015). Pulmonary function in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab, 28(1-2): 163-169.
[54] Guvener N, Tutuncu NB, Akcay S, Eyuboglu F, Gokcel A (2003). Alveolar gas exchange in patients with type 2 diabetes mellitus. Endocr J, 50(6): 663-667.
[55] Shah SH, Sonawane P, Nahar P, Vaidya S, Salvi S (2013). Pulmonary function tests in type 2 diabetes mellitus and their association with glycemic control and duration of the disease. Lung India, 30(2): 108-112.
[56] Wheatley CM, Baldi JC, Cassuto NA, Foxx-Lupo WT, Snyder EM (2011). Glycemic control influences lung membrane diffusion and oxygen saturation in exercise-trained subjects with type 1 diabetes: alveolar-capillary membrane conductance in type 1 diabetes. Eur J Appl Physiol, 111(3): 567-578.
[57] Brownlee M (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414(6865): 813-820.
[58] Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A, et al. (2011). The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev, 7(5): 313-324.
[59] Lapolla A, Fedele D (1993). [Oxidative stress and diabetes: role in the development of chronic complications]. Minerva Endocrinol, 18(3): 99-108.
[60] Redmann M, Darley-Usmar V, Zhang J (2016). The Role of Autophagy, Mitophagy and Lysosomal Functions in Modulating Bioenergetics and Survival in the Context of Redox and Proteotoxic Damage: Implications for Neurodegenerative Diseases. Aging Dis, 7(2): 150-162.
[61] Yan LJ (2014). Positive oxidative stress in aging and aging-related disease tolerance. Redox Biol, 2C: 165-169.
[62] Yan LJ (2014). Protein redox modification as a cellular defense mechanism against tissue ischemic injury. Oxid Med Cell Longev, 2014: 343154.
[63] Zheng H, Wu J, Jin Z, Yan LJ (2016). Protein Modifications as Manifestations of Hyperglycemic Glucotoxicity in Diabetes and Its Complications. Biochem Insights, 9: 1-9.
[64] Radi R (1998). Peroxynitrite reactions and diffusion in biology. Chem Res Toxicol, 11(7): 720-721.
[65] Di Naso FC, de Mello RN, Bona S, Dias AS, Porawski M, Ferraz Ade B, et al. (2010). Effect of Agaricus blazei Murill on the pulmonary tissue of animals with streptozotocin-induced diabetes. Exp Diabetes Res, 2010: 543926.
[66] Nishikawa T, Sasahara T, Kiritoshi S, Sonoda K, Senokuchi T, Matsuo T, et al. (2003). Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care, 26(5): 1507-1512.
[67] Xiong XQ, Wang WT, Wang LR, Jin LD, Lin LN (2012). Diabetes increases inflammation and lung injury associated with protective ventilation strategy in mice. Int Immunopharmacol, 13(3): 280-283.
[68] Que Y, Shen X (2016). Changes in blood monocyte Toll-like receptor and serum surfactant protein A reveal a pathophysiological mechanism for community-acquired pneumonia in patients with type 2 diabetes. Intern Med J, 46(2): 213-219.
[69] Baynes JW, Thorpe SR (1999). Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes, 48(1): 1-9.
[70] Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986). Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science, 232(4758): 1629-1632.
[71] Hammes HP, Weiss A, Hess S, Araki N, Horiuchi S, Brownlee M, et al. (1996). Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest, 75(3): 325-338.
[72] Vlassara H, Bucala R, Striker L (1994). Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest, 70(2): 138-151.
[73] Chilelli NC, Burlina S, Lapolla A (2013). AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a “glycoxidation-centric” point of view. Nutr Metab Cardiovasc Dis, 23(10): 913-919.
[74] Nagai R, Ikeda K, Higashi T, Sano H, Jinnouchi Y, Araki T, et al. (1997). Hydroxyl radical mediates N epsilon-(carboxymethyl)lysine formation from Amadori product. Biochem Biophys Res Commun, 234(1): 167-172.
[75] Matsuse T, Ohga E, Teramoto S, Fukayama M, Nagai R, Horiuchi S, et al. (1998). Immunohistochemical localisation of advanced glycation end products in pulmonary fibrosis. J Clin Pathol, 51(7): 515-519.
[76] Brownlee M, Cerami A, Vlassara H (1988). Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med, 318(20): 1315-1321.
[77] Yamagishi S, Nakamura K, Matsui T (2006). Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Curr Drug Discov Technol, 3(1): 83-88.
[78] Zong H, Ward M, Stitt AW (2011). AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep, 11(4): 244-252.
[79] Goldin A, Beckman JA, Schmidt AM, Creager MA (2006). Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation, 114(6): 597-605.
[80] Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M (1995). PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int, 48(1): 111-117.
[81] Yan LJ (2014). Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress. J Diabetes Res, 2014: 137919.
[82] Boesten DM, von Ungern-Sternberg SN, den Hartog GJ, Bast A (2015). Protective Pleiotropic Effect of Flavonoids on NAD(+) Levels in Endothelial Cells Exposed to High Glucose. Oxid Med Cell Longev, 2015: 894597.
[83] Lopez-Lopez JG, Moral-Sanz J, Frazziano G, Gomez-Villalobos MJ, Flores-Hernandez J, Monjaraz E, et al. (2008). Diabetes induces pulmonary artery endothelial dysfunction by NADPH oxidase induction. Am J Physiol Lung Cell Mol Physiol, 295(5): L727-732.
[84] Gumieniczek A, Hopkala H, Wojtowicz Z, Wysocka M (2002). Changes in antioxidant status of lung tissue in experimental diabetes in rabbits. Clinical Biochemistry, 35(2): 147-149.
[85] Lei SQ, Li YA, Liu HM, Yu H, Wang H, Xia ZY (2012). Effects of N-Acetylcysteine on Nicotinamide Dinucleotide Phosphate Oxidase Activation and Antioxidant Status in Heart, Lung, Liver and Kidney in Streptozotocin-Induced Diabetic Rats. Yonsei Medical Journal, 53(2): 294-303.
[86] Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, et al. (2009). RAGE-induced Cytosolic ROS Promote Mitochondrial Superoxide Generation in Diabetes. Journal of the American Society of Nephrology, 20(4): 742-752.
[87] Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, et al. (1996). RAGE - A novel cellular receptor for advanced glycation end products. Diabetes, 45: S77-S80.
[88] Zhong P, Wu L, Qian Y, Fang Q, Liang D, Wang J, et al. (2015). Blockage of ROS and NF-kappaB-mediated inflammation by a new chalcone L6H9 protects cardiomyocytes from hyperglycemia-induced injuries. Biochim Biophys Acta, 1852(7): 1230-1241.
[89] Sun CK, Lee FY, Sheu JJ, Yuen CM, Chua S, Chung SY, et al. (2009). Early combined treatment with cilostazol and bone marrow-derived endothelial progenitor cells markedly attenuates pulmonary arterial hypertension in rats. J Pharmacol Exp Ther, 330(3): 718-726.
[90] Yagi O, Aoshiba K, Nagai A (2006). Activation of nuclear factor-kappaB in airway epithelial cells in patients with chronic obstructive pulmonary disease. Respiration, 73(5): 610-616.
[91] Zhang F, Yang F, Zhao H, An Y (2015). Curcumin alleviates lung injury in diabetic rats by inhibiting NF-kappaB pathway. Clin Exp Pharmacol Physiol.
[92] Martins JO, Ferracini M, Anger DB, Martins DO, Ribeiro LF, Jr., Sannomiya P, et al. (2010). Signaling pathways and mediators in LPS-induced lung inflammation in diabetic rats: role of insulin. Shock, 33(1): 76-82.
[93] Bey EA, Xu B, Bhattacharjee A, Oldfield CM, Zhao X, Li Q, et al. (2004). Protein kinase C delta is required for p47phox phosphorylation and translocation in activated human monocytes. J Immunol, 173(9): 5730-5738.
[94] Wu J, Yan LJ (2015). Streptozotocin-induced type 1 diabetes in rodents as a model for studying mitochondrial mechanisms of diabetic beta cell glucotoxicity. Diabetes Metab Syndr Obes, 8: 181-188.
[95] Jin Z, Wu J, Yan LJ (2016). Chemical Conditioning as an Approach to Ischemic Stroke Tolerance: Mitochondria as the Target. Int J Mol Sci, 17 (3).
[96] Onyango IG, Dennis J, Khan SM (2016). Mitochondrial Dysfunction in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies. Aging Dis, 7(2): 201-214.
[97] Bonomini F, Rodella LF, Rezzani R (2015). Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis, 6(2): 109-120.
[98] Victor VM, Rocha M, Herance R, Hernandez-Mijares A (2011). Oxidative stress and mitochondrial dysfunction in type 2 diabetes. Curr Pharm Des, 17(36): 3947-3958.
[99] Fernyhough P, Jonathan M (2014). Mechanisms of disease: Mitochondrial dysfunction in sensory neuropathy and other complications in diabetes. Handb Clin Neurol, 126: 353-377.
[100] Blake R, Trounce IA (2014). Mitochondrial dysfunction and complications associated with diabetes. Biochim Biophys Acta, 1840(4): 1404-1412.
[101] Bhatt MP, Lim YC, Kim YM, Ha KS (2013). C-peptide activates AMPKalpha and prevents ROS-mediated mitochondrial fission and endothelial apoptosis in diabetes. Diabetes, 62(11): 3851-3862.
[102] Towler DA (2013). Mitochondrial ROS deficiency and diabetic complications: AMP[K]-lifying the adaptation to hyperglycemia. J Clin Invest, 123(11): 4573-4576.
[103] Anthonsen S, Larsen J, Pedersen PL, Dalgaard LT, Kvetny J (2013). Basal and T(3)-induced ROS production in lymphocyte mitochondria is increased in type 2 diabetic patients. Horm Metab Res, 45(4): 261-266.
[104] Lindblom R, Higgins G, Coughlan M, de Haan JB (2015). Targeting Mitochondria and Reactive Oxygen Species-Driven Pathogenesis in Diabetic Nephropathy. Rev Diabet Stud, 12(1-2): 134-156.
[105] Yu T, Sheu SS, Robotham JL, Yoon Y (2008). Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species. Cardiovasc Res, 79(2): 341-351.
[106] Yan LJ, Rajasekaran NS, Sathyanarayanan S, Benjamin IJ (2005). Mouse HSF1 disruption perturbs redox state and increases mitochondrial oxidative stress in kidney. Antioxid Redox Signal, 7(3-4): 465-471.
[107] Skulachev VP (1998). Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett, 423(3): 275-280.
[108] Yan LJ, Christians ES, Liu L, Xiao X, Sohal RS, Benjamin IJ (2002). Mouse heat shock transcription factor 1 deficiency alters cardiac redox homeostasis and increases mitochondrial oxidative damage. EMBO J, 21(19): 5164-5172.
[109] Ni R, Cao T, Xiong S, Ma J, Fan GC, Lacefield JC, et al. (2016). Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy. Free Radic Biol Med, 90: 12-23.
[110] Sivitz WI, Yorek MA (2010). Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal, 12(4): 537-577.
[1] Tseng Chin-Hsiao. Metformin and the Risk of Dementia in Type 2 Diabetes Patients[J]. Aging and disease, 2019, 10(1): 37-48.
[2] Antonina Luca, Carmela Calandra, Maria Luca. Molecular Bases of Alzheimer’s Disease and Neurodegeneration: The Role of Neuroglia[J]. Aging and disease, 2018, 9(6): 1134-1152.
[3] Changhong Ren, Hang Wu, Dongjie Li, Yong Yang, Yuan Gao, Yunneng Jizhang, Dachuan Liu, Xunming Ji, Xuxiang Zhang. Remote Ischemic Conditioning Protects Diabetic Retinopathy in Streptozotocin-induced Diabetic Rats via Anti-Inflammation and Antioxidation[J]. Aging and disease, 2018, 9(6): 1122-1133.
[4] Yong-Fei Zhao, Qiong Zhang, Jian-Feng Zhang, Zhi-Yin Lou, Hen-Bing Zu, Zi-Gao Wang, Wei-Cheng Zeng, Kai Yao, Bao-Guo Xiao. The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson’s Disease[J]. Aging and disease, 2018, 9(5): 785-797.
[5] Fan Liu, Jianfei Lu, Anatol Manaenko, Junjia Tang, Qin Hu. Mitochondria in Ischemic Stroke: New Insight and Implications[J]. Aging and disease, 2018, 9(5): 924-937.
[6] Eckert Schamim H, Gaca Janett, Kolesova Nathalie, Friedland Kristina, Eckert Gunter P, Muller Walter E. Mitochondrial Pharmacology of Dimebon (Latrepirdine) Calls for a New Look at its Possible Therapeutic Potential in Alzheimer’s Disease[J]. Aging and disease, 2018, 9(4): 729-744.
[7] Zhang Li, Hao Junwei, Zheng Yan, Su Ruijun, Liao Yajin, Gong Xiaoli, Liu Limin, Wang Xiaomin. Fucoidan Protects Dopaminergic Neurons by Enhancing the Mitochondrial Function in a Rotenone-induced Rat Model of Parkinson’s Disease[J]. Aging and disease, 2018, 9(4): 590-604.
[8] Morroni Fabiana, Sita Giulia, Graziosi Agnese, Turrini Eleonora, Fimognari Carmela, Tarozzi Andrea, Hrelia Patrizia. Neuroprotective Effect of Caffeic Acid Phenethyl Ester in A Mouse Model of Alzheimer’s Disease Involves Nrf2/HO-1 Pathway[J]. Aging and disease, 2018, 9(4): 605-622.
[9] Yang Yao-Chih, Tsai Cheng-Yen, Chen Chien-Lin, Kuo Chia-Hua, Hou Chien-Wen, Cheng Shi-Yann, Aneja Ritu, Huang Chih-Yang, Kuo Wei-Wen. Pkcδ Activation is Involved in ROS-Mediated Mitochondrial Dysfunction and Apoptosis in Cardiomyocytes Exposed to Advanced Glycation End Products (Ages)[J]. Aging and disease, 2018, 9(4): 647-663.
[10] Yan Tao, Venkat Poornima, Chopp Michael, Zacharek Alex, Yu Peng, Ning Ruizhuo, Qiao Xiaoxi, Kelley Mark R., Chen Jieli. APX3330 Promotes Neurorestorative Effects after Stroke in Type One Diabetic Rats[J]. Aging and disease, 2018, 9(3): 453-466.
[11] Zhen Jie, Lin Tong, Huang Xiaochen, Zhang Huiqiang, Dong Shengqi, Wu Yifan, Song Linlin, Xiao Rong, Yuan Linhong. Association of ApoE Genetic Polymorphism and Type 2 Diabetes with Cognition in Non-Demented Aging Chinese Adults: A Community Based Cross-Sectional Study[J]. Aging and disease, 2018, 9(3): 346-357.
[12] Zhang Meng, Deng Yong-Ning, Zhang Jing-Yi, Liu Jie, Li Yan-Bo, Su Hua, Qu Qiu-Min. SIRT3 Protects Rotenone-induced Injury in SH-SY5Y Cells by Promoting Autophagy through the LKB1-AMPK-mTOR Pathway[J]. Aging and disease, 2018, 9(2): 273-286.
[13] Mari L. Sbardelotto,Giulia S. Pedroso,Fernanda T. Pereira,Helen R. Soratto,Stella MS. Brescianini,Pauline S. Effting,Anand Thirupathi,Renata T. Nesi,Paulo CL. Silveira,Ricardo A. Pinho. The Effects of Physical Training are Varied and Occur in an Exercise Type-Dependent Manner in Elderly Men[J]. A&D, 2017, 8(6): 887-898.
[14] Tia R. Tidwell,Kjetil Søreide,Hanne R. Hagland. Aging, Metabolism, and Cancer Development: from Peto’s Paradox to the Warburg Effect[J]. A&D, 2017, 8(5): 662-676.
[15] Guofen Gao, Nan Zhang, Yue-Qi Wang, Qiong Wu, Peng Yu, Zhen-Hua Shi, Xiang-Lin Duan, Bao-Lu Zhao, Wen-Shuang Wu, Yan-Zhong Chang. Mitochondrial Ferritin Protects Hydrogen Peroxide-Induced Neuronal Cell Damage[J]. A&D, 2017, 8(4): 458-470.
Viewed
Full text


Abstract

Cited

  Shared   
Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail: editorial@aginganddisease.org
Powered by Beijing Magtech Co. Ltd